2. The PSAEFI in Brazil has certain features that distinguish it from similar systems in developed countries such as the United States and those in the European Union [4] and [26]. Their objectives are less comprehensive, and have operated exclusively under the auspices of the NIP [12] and [24] and are not formally linked to a regulatory health agency. Nevertheless, find protocol a committee, created in 2008, has been charged with fostering joint activities and promoting cooperation between NIP and the regulatory

health agency in terms of the sharing information related AEFIs in order to improve the vaccine safety in Brazil. The Brazilian passive SAEFI system, despite its relatively lower degree of complexity, is capable of adequately monitoring vaccine safety, as well as being capable of responding promptly to the questions and apprehensions of the populace. One example of such public concern is provided by the DTwP/Hib vaccine. Soon after the introduction of this vaccine into the routine Brazilian vaccination schedule, there were rumors that the incidence of severe AEFIs, especially HHEs, had increased in various states. The NIP staff immediately launched a study to investigate the questions raised,

ultimately proving that such fears were unfounded [13]. This indicates the usefulness and timeliness of the PSAEFI, as well as the importance, in such situations, of developing epidemiological studies to complement the PSAEFI data [26]. Despite the limitations of passive surveillance [26], the results obtained in the present study are consistent with those found in buy CHIR-99021 the literature. The interval between the administration of the vaccine and the occurrence of the AEFI, especially for HHEs and convulsions, was similar to that described in studies evaluating

the DTwP or DTwP/Hib vaccine [13] and [25]. Our finding that the risk of AEFI with DTwP/Hib vaccine decreases progressively over the course of the vaccination schedule is also in keeping with the findings of other authors [13]. The proportion of severe AEFIs found in the present study should be interpreted only with caution, since it is considerably higher than that found in other studies employing passive surveillance [27] and [28]. Given that the reactogenicity of Brazilian DTwP/Hib vaccine is comparable with the same vaccine registered in countries such as Israel [29] and [30], this discrepancy can be attributed to the case definition adopted in Brazil [23], which downplays mild events and late-onset AEFIs, resulting in an overestimation of the proportion of severe events [13], [24] and [28]. The use of paracetamol, which the NIP recommends for children with a history of AEFI, might decrease the incidence of mild AEFI. However the frequency of paracetamol use in Brazil is unknown [31]. The number, probably underestimated, of cases treated in hospitals, should not be overlooked.

Les signes bulbaires selleck products inaugurent la maladie dans un tiers des cas. Elle réalise un tableau de paralysie labio-glosso-pharyngo-laryngée. Les troubles de la phonation et

de l’élocution se traduisent par une dysarthrie, une voix mal articulée, qui devient nasonnée puis incompréhensible. Les troubles de la déglutition prédominent pour les liquides. À l’examen, la langue est le siège de fasciculations visibles au repos, puis d’une atrophie des bords latéraux. La mobilité de la langue et du voile diminue, le réflexe du voile reste longtemps présent. Lors d’une atteinte pseudo-bulbaire, les réflexes naso-palpébral et massétérin sont vifs et peuvent s’associer à un rire et pleurer spasmodiques, et à un clonus

du menton, avec dissociation automatico-volontaire du voile. Des formes inhabituelles peuvent contribuer au retard diagnostique et nécessitent le plus souvent une stratégie d’examens complémentaires. Elle se caractérise par une atteinte bilatérale, dont le début a été asynchrone pendant quelques semaines, avec à l’examen un déficit moteur, une amyotrophie Selleckchem SAHA HDAC distale des membres inférieurs et une abolition des réflexes achilléens. Les réflexes rotuliens sont parfois vifs. L’évolution est classiquement lente avec apparition secondaire d’une atteinte des membres supérieurs et d’un syndrome pyramidal. La stase salivaire, la dysarthrie et la dysphonie isolées posent le problème du diagnostic différentiel avec une myasthénie, une pathologie very ORL. L’amyotrophie et le déficit moteur touchent les épaules (muscles sus et sous-épineux, deltoïdes). Les ROT sont abolis et il n’y a pas de signe clinique d’atteinte du NMC au début. La progression du déficit aux bras, aux avant-bras et aux muscles intrinsèques des mains aboutit à une diplégie brachiale (aspect de bras en fléau). Les signes d’atteinte pyramidale surviennent plus tard au cours de l’évolution. Elle comporte un syndrome tétrapyramidal et pseudo-bulbaire. L’évolution est

très progressive, supérieure à 3 ans, et l’atteinte du NMP est au second plan, mise en évidence parfois sur les seules données de l’ENMG. La présence de troubles cognitifs, notamment fronto-temporaux, peut rendre plus difficile le diagnostic et le retarder. Trente à 50 % des patients ont un syndrome dysexécutif et 15 % une démence fronto-temporale [57]. Elle est de diagnostic particulièrement difficile en raison de poly-pathologies associées. S’il n’est pas systématiquement évoqué, le diagnostic est souvent retardé et porté alors au stade d’état grabataire. Elles se caractérisent par un début en moyenne plus précoce de 10 ans (extrêmes de 15 ans et 85 ans). Elles représentent environ 10 % des cas.

Briefly, nitrocellulose bottom 96-well plates (MILLIPORE) were coated overnight at 4 °C with anti-IFN-γ monoclonal antibody (clone R4-6A2; trans-isomer clinical trial BD Biosciences) diluted in PBS. Plates were washed and blocked for 2 h with DMEM supplemented with 10% FCS. Spleen

cells of immunized mice were prepared in DMEM supplemented with 10% FCS and recombinant IL-2 (100 U/ml). Splenocytes were seeded at a density of 5 × 105 cells/well and stimulated with F3 antigenic fraction (5 μg/ml) during 20 h at 37 °C, 5% CO2. Plates were washed and incubated for 4 h, at room temperature, with a biotin-conjugate anti-mouse IFN-γ monoclonal antibody (clone XMG1.2; BD Biosciences) and, after the next wash step, with peroxidase-labeled streptavidin, for 2 h at room temperature. Reactions were detected with a peroxidase substrate containing 3,3′-diaminobenzidine MK0683 tetrahydrochloride (1 mg/ml) and 30% hydrogen peroxide solution (1 μl/ml) in 50 mM Tris–HCL buffer, pH = 7.5. Reactions were stopped under running water, and spots were counted on a S5 Core ELISPOT Analyser (CTL). Four weeks after the boost immunization, mice were infected orally with 20 cysts of P-Br strain of T. gondii, obtained from macerated brains of infected Swiss-Webster reservoirs suspended in PBS. Animals were sacrificed 8 weeks after the challenge. The brains were collected, macerated and suspended in 1 ml of PBS. Cysts were counted, in

duplicates, under light microscope, in 10 μl of brain suspensions. All results were evaluated for their statistic significance by Student’s t-test (parametric data) or by Mann–Whitney test (non-parametric data) performed with Minitab version 14. Normal distribution of samples was assessed by Anderson Darling software. The recombinant NA38-SAG2 segment was developed to carry the SAG2 sequence of T. gondii flanked by the duplicated 3′ promoter and the extended native 5′ terminal sequence of 70 nucleotides corresponding to 28 nt of the 5′ promoter and a duplication

of the mafosfamide last 42 nt of the NA coding sequence, located upstream the promoter ( Fig. 1). Recombinant Influenza A viruses harboring the dicistronic NA38-SAG2 segment (FLU-SAG2) were generated using the 12 plasmid-driven reverse genetics, as previously described [41]. Recombinant FLU-SAG2 viruses displayed a slightly altered phenotype ( Fig. 2A), but showed infectious titers (9.2 ± 3.2 × 107 pfu/ml) similar to wild type vNA (1.4 × 108 pfu/ml). The presence of SAG2 in recombinant NA segments was assessed in three FLU-SAG2 clones by RT-PCR with primers that allowed the amplification of the entire region of insertion of SAG2. As shown in Fig. 2B, amplification products of the expected size (∼900 bp) were observed for all clones analyzed. Moreover, these amplicons were sequenced and showed no mutation in SAG2 sequence as well as in the internal 3′promoter (data not shown). Taking together, these results showed that FLU-SAG2 viruses are genetically stable in cell culture.

Statistical significance differences among the experimental groups concerning level of antigen-specific

antibodies, tick count and cattle body weight gain was analyzed by Student’s t test. Data were expressed as mean ± S.E.M. of each group. A p value of less than 0.05 was considered significant. Statistical analysis was 3-Methyladenine order performed using GraphPad Prism 3.0 (GraphPad Software Inc., San Diego, USA) software. The recombinant proteins BYC, GST-Hl and VTDCE were expressed in E. coli strains and purified by affinity chromatography. The purity of the three recombinant proteins was analyzed by a 14% SDS-PAGE ( Fig. 1A). All preparations showed a major protein band for rBYC, rGST-Hl, and rVTDCE in the gel, and these bands matched the predicted molecular masses for respective proteins. Dot blot analysis revealed an increased antibody recognition level of vaccinated bovine sera (collected at day 78) to the three recombinant proteins, compared to the vaccinated

bovine pre-immune sera (day 1) (Fig. 2). Compared to day 1, the level of recognition from vaccinated cattle sera on day 78 for rGST-Hl, rVTDCE and rBYC increased by more than 6, 10, and 2 times, respectively. The level of recognition remained constant at the end of the experiment (day 127) for rGST-Hl, reducing by half for rVTDCE, and returning to pre-immunization level for rBYC. Also, the level of recognition measured from vaccinated cattle sera was approximately 8, 4, and 2.5 times higher for rGST-Hl, rVTDCE, and rBYC respectively, than those recorded from animals injected with placebo on day 78. Western blot revealed that sera from one representative bovine selleck screening library of the vaccinated group recognize all recombinant proteins (Fig. 1B). The proteins rBYC, rGST-Hl and rVTDCE were not recognized by pre-immune serum of this animal. The reduction in the number of ticks attached to bovines conferred by immunization with rBYC, rGST-Hl and rVTDCE is shown in Fig. 3 and Table 1. In the first three counts, tick number means from both groups were similar. From the fourth count on (days 36–127), means in the two groups were statistically different, except for day 57. During this period, bovines

vaccinated with recombinant proteins showed statistical reductions that ranged from 35.3 to 61.6% (Table 1) in the number of semi-engorged ticks, SB-3CT as compared with the control group. Interestingly, even before the immunization period had ended it was already possible to detect a drop in tick infestation (Fig. 3, day 36). Also, there was an increase in cattle body weight in both groups between days 1 and 127, although the gain was statistically higher in the vaccinated group (Fig. 4). In the vaccinated and control cattle groups, body weight gain was 39% and 25%, respectively. Tick vaccines derived from the gut antigen Bm86 have been extensively investigated in the quest for a suitable tick control method. This antigen was shown to be partially protective against R.

The PRNT method used was a serum dilution, constant virus PRNT50 performed in LLC-MK2 cells, as described by Russell et al. [11]. Paired serum samples from all

subjects were tested for antibodies against wild-type Beijing-1 strain. JE viruses belong to JE virus genotype III, the same genotype as LJEV. The end point for neutralization was the highest dilution of serum reducing plaques by 50%, compared with a negative serum control, determined by probit analysis. Seroprotection after LJEV was defined as at least 1:10 dilution as recommended by the World Health Organization (WHO) [12]. GMCs for measles and GMTs for JE were determined by ELISA and PRNT, respectively. Four weeks after measles vaccination, measles seroprotection rates find more were 88.6% (Group 1), 91.8% (Group 2), and 86.5% (Group 3) (Table 2). As per the pre-specified primary objective, selleck screening library Group 2 (concomitant MV and LJEV) measles seroprotection rates were

noninferior to Group 3 (MV alone) seroprotection rates with the lower bound of the 95% CI of the difference ≥−10% [difference (95% CI) = 5.3% (−0.9%; 11.5%)]. The GMCs for measles antibodies in Groups 1, 2, and 3 were 319, 302, and 263 mIU/mL, respectively (Table 2). JE seroprotection rates at 4 weeks postvaccination were 92.1% (Group 1), 90.5% (Group 2), and 90.6% (Group 3). Group 2 (concomitant MV and LJEV) was noninferior to Group 1 (LJEV alone) in terms of JE seroprotection rates [difference (95% CI) = −1.5% (−8.3%; 5.3%)] with the lower interval of the 95% CI ≥−10%. The GMTs for JE antibodies in Groups 1, 2, and 3 were 203, 155, and 139, respectively (Table 2). “
“The authors regret the

following errors in Sections 2.7, MRIP 3.5 and 3.6 of their article Karanam et al., Vaccine 27 (2009) 1040–1049, and apologize for any confusion: at study entry, the three macaques numbered 746, 831 and 811 were aged 20.9, 10.5 and 14.4 years, respectively, and weighed 20.8 lbs, 19.2 lbs and 22.8 lbs, respectively. Each animal was vaccinated i.m. the deltoid on days 0, 26, 60 and the final bleed was day 89. The corrected values are underlined. “
“During the past decade an unprecedented number of important new vaccines were approved for use in economically advantaged countries but subsequent population access was seldom speedily achieved. The process by which new vaccines gain approval and ultimately reach consumers is increasingly complex as vaccine technology advances and costs increase. The approval process begins with in-depth review of vaccine properties and performance by the national biologics regulator, the successful conclusion of which is marketing authorization (or licensure in some countries). In theory, vaccine consumption can begin at this point. However, vaccines are best provided to populations through funded public programs, consideration of which requires additional review, usually by the national immunization technical advisory group (NITAG) [1].

Whereas the complex 2 shows an irreversible peak at 0.44 V at a scan rate

of 100 mVs−1. The redox process is assigned to CuII/CuI couple. 30 and 31 The characterization of DNA recognition by transition metal complex has been aided by the DNA cleavage chemistry that is associated with redox-active or photo-activated metal complexes.32 Many copper complexes have been shown to cleave DNA in the presence of H2O2 due to their ability to behave like a Fenton catalyst.33 The ability of present complexes to effect DNA cleavage www.selleckchem.com/products/Methazolastone.html was monitored by gel electrophoresis using supercoiled pUC19 DNA in Tris–HCl buffer. Fig. 1 shows the nuclease activity of the complexes in the presence and absence of hydrogen peroxide. Lane 1 indicates the control DNA without any additives. Lane 2 shows the activity of DNA in the presence of peroxide. As seen in lanes 3–5, incubation of the complexes 1–3 alone with DNA could not bring about any apparent

cleavage. This confirms that the present copper(II) complexes are not capable of bringing about any hydrolytic cleavage of DNA. The reason behind is that the hydrolytic cleavage requires AZD8055 coordinative binding of the copper(II) complex to the phosphate moiety of the nucleic acid.34 Interestingly all the three complexes show DNA cleavage activity at a concentration of 48 μM. But the cleavage efficiency of complex 2 was found to be significantly lower than that of the other two complexes. It is believed that when the present

redox active copper complexes were interacted with DNA in the presence of hydrogen peroxide as an oxidant hydroxyl radicals Cell press might be produced.22, 23 and 24 These hydroxyl radicals are responsible for cleavage of DNA. In order to establish the reactive species responsible for the cleavage of DNA, we carried out the experiment in the presence of histidine and DMSO. As seen in lanes 2–4 in Fig. 2, the cleavage activity was not found to be inhibited in the presence of histidine. This rules out the involvement of singlet oxygen in the cleavage activity. However, as seen in lanes 5–7, the cleavage activity was inhibited significantly in the presence of DMSO. This conclusively shows the involvement of the hydroxyl radical in the observed nuclease activity of the copper(II) complexes in the presence of peroxide. In summary, we have synthesized and characterized three new mononuclear mixed ligand copper(II) complexes having tridentate reduced Schiff bases and planar NN-donor heterocyclic bases. All the complexes show nuclease activity in the presence of hydrogen peroxide in converting supercoiled pUC19 DNA to its nicked circular form. The cleavage reactions are found to be inhibited in the presence of hydroxyl radical scavenger DMSO. All authors have none to declare. The authors thank the Head, Department of Chemistry, UDC, Trichy for providing laboratory facilities. “
“Copper is an essential trace element in plants and animals, but not some microorganisms.

Surveillance subjects and methods elsewhere learn more in the UK are different and will offer complementary evidence regarding the impact and effectiveness of the UK immunisation programme. In England, this surveillance will continue in order to determine the extent of herd- protection and of cross-protection and any type-replacement. To address these remaining questions future analysis will include larger numbers of surveillance specimens, more time since immunisation,

more sampling from the birth-cohorts with high coverage of routine immunisation and vaccine effectiveness will be estimated once immunisation status has been obtained for some subjects. This work was supported by Public Health England. KS and ONG initiated and designed the surveillance. RHJ, DM and KS conducted the sample collection CX 5461 and data management. SB,

KP and PM performed the HPV testing. MJ contributed to data analysis and interpretation, particularly relating to mathematical modelling. DM conducted the statistical analysis. All authors had full access to all of the data (including statistical reports and tables) in the study and can take responsibility for the integrity of the data and the accuracy of the data analysis. DM and KS wrote the first draft of the manuscript. All authors contributed to and approved the final analysis and manuscript. None declared. We thank staff at participating laboratories who have provided NCSP specimens for testing: Bridget Reed, Ian Robinson and Mike Rothburn at University Hospital Aintree; Heather Etherington, Amanda Ronson-Binns and Susan Smith at Leeds Teaching Hospital; Nick Doorbar and David Frodsham at University Hospital of North Staffordshire; Gail Carr and Laura Ryall at Public Health Laboratory, Cambridge, Addenbrooke’s Hospital; Samir Dervisevic and Emma Meader at Norfolk and Norwich University Hospital; Roberta Bourlet and Marie Payne at East Kent Hospitals University; Allyson Lloyd

and Colin Walker at Queen Alexandra Hospital; Vic Ellis at Royal Cornwall Hospital; Caroline Carder at University Parvulin College London Hospital; Ruth Hardwick, Tacim Karadag and Paul Michalczyk at University Hospital Lewisham. We thank the National Chlamydia Screening Programme (NCSP), particularly Alireza Talebi and Bersebeh Sile and the Chlamydia Screening Offices, for supporting the collection of NCSP specimens, assistance recruiting laboratories and conducting data linking. Thanks also to Heather Northend, Tracey Cairns and Krishna Gupta for help with data-processing, Sarah Woodhall for helpful discussions about changing chlamydia screening trends, Sarika Desai for developing the protocol for the post-immunisation surveillance, Natasha de Silva, Sara Bissett, and John Parry for helping to establish and maintain the HPV assay, and Tom Nichols for advice on data analysis. “
“Rotavirus is the most common cause of severe diarrhea in children under 5 years of age and the leading cause of diarrheal deaths worldwide.

Finally, although most of the research on vaccine hesitancy is conducted in high income countries [5], the majority of IMs interviewed in this study were from low and middle income countries. Indeed, the results could have differed if more IMs from high income countries had been interviewed, as they may be more aware of vaccine

hesitancy and its determinants because this field of research is more developed in those countries. The choice of countries also limited the possibility of assessing differences in the perspective of IMs between regions and economic categories. To Vemurafenib datasheet conclude, understanding the specific concerns of the various groups of vaccine-hesitant individuals,

including health professionals, is important as hesitancy may result in vaccination delays or refusals. Vaccine hesitancy Selleckchem ZD1839 is an individual behaviour, but is also the result of broader societal influences and should always be looked at in the historical, political and socio-cultural context in which vaccination takes place. The results of this study will be used by the SAGE Working Group on vaccine hesitancy in preparing its recommendations to the SAGE, which will then consider potential global health policy implications. The findings highlight the need to ensure that health professionals and those involved in immunization programmes are well informed about vaccine hesitancy and are able to identify and address its determinants. There is a need to strengthen the capacity of countries to identify the context-specific roots of vaccine hesitancy and to develop adapted strategies to address them. We thank the participating national IMs and WHO staff at the regional and national offices for arranging the interviews. We also thank the Bay 11-7085 members of the SAGE Working Group on vaccine hesitancy and the WHO SAGE secretariat for their contribution in the design of the study

and interpretation of the results: Mohuya Chaudhuri, Philippe Duclos, Bruce Gellin, Susan Goldstein, Juhani Eskola, Heidi Larson, Xiaofeng Liang, Noni MacDonald, Mahamane Laouli Manzo, Arthur Reingold, Dilian Francisca Toro Torres, Kinzang Tshering and Yuqing Zhou. This study was sponsored by the World Health Organization. Conflict of interest statement Nothing to declare. “
“Adjuvanted RTS,S (RTS,S/AS), a candidate malaria vaccine consisting of the recombinant protein RTS,S, which is comprised of sequences of the circumsporozoite protein (CSP) and hepatitis B surface antigen (HBsAg), is uniquely able to protect malaria-naïve adult subjects after experimental malaria challenge against infection [1], [2], [3], [4] and [5], and African adults and children exposed to diverse strains against clinical and severe disease [6], [7], [8], [9], [10] and [11].

The results showed a statistically significant decrease in pain of 20% for the active treatment compared to the control intervention, suggesting a clinically important difference in knee pain. This double-blinded randomised crossover trial was well conducted, even though the study did not involve a control group without any interventions making it hard to state the possible placebo effect. Furthermore, a high drop-out rate was reported (30%),

Pomalidomide but the study was adequately powered to detect a clinically relevant difference in knee pain. To be able to demonstrate the efficacy of multiple orthotic modalities, adherence to treatment is important. This study emphasised adherence to intervention by giving educational Selleck ROCK inhibitor messages, assessed adherence by calling the patients every week, and asked the included

patients to diary record their daily use of orthoses. The participants wore the orthoses on average more than 3 hours a day, however, the doseresponse for orthoses was not appropriately documented. The study participants were predominantly those with medial knee osteoarthritis, without severe co-morbidities, and obese individuals with high average body mass index (> 32.8). Even though the present study showed a significant and clinical reduction in knee pain for obese individuals treated with multiple orthotic modalities, both weight loss and exercises should be the first choice treatment for these individuals. However, recommendations involving use of multiple orthotic modalities more than 3 hours a day seem to be an effective additional treatment option for obese patients aged over 60 years with medial compartment knee osteoarthritis. Unoprostone “
“The SPHERE 12 (Somatic and Psychological HEalth REport) is a 12-item, self-rated tool to screen for anxiety, depression, and somatisation

in primary care. The SPHERE 12 is a shortened version of the SPHERE 34 (Hickie et al 2001a), which was derived from the General Health Questionnaire (GHQ-30), the Schedule of Fatigue and Anergia, the Illness, Fatigue and Irritability Questionnaire, and the Diagnostic Interview Schedule for somatisation. Six items of the SPHERE 12 assess psychological health (PSYCH subscale) and six assess physical symptoms and fatigue (SOMA subscale). Instruction to the patient and scoring: Patients rate the PSYCH and SOMA items in terms of how much each has troubled them over the past few weeks on a scale of 0–2 (0 = never troubled, 2 = troubled most of the time). A score of two or more on the PSYCH subscale reflects the presence of a possible mental disorder (anxiety or depression) and three or more on the SOMA subscale reflects the presence of a possible somatic disorder (somatoform disorder or somatisation) (Hickie et al 2001a, Wilhelm et al 2008). Positive scores on both scales reflect a mixed presentation.

Agreement between antibody reactivity against L1L2 pseudoviruses and L1 VLP representing non-vaccine HPV types was weaker with VLP ELISA antibody titers generally an order of magnitude higher than the corresponding pseudovirus neutralizing titers [4] and [26]. To

examine the discrepancy between cross-reactive antibody profiles, both sets of serological data were subjected to hierarchical clustering. buy VE-822 This approach has been used for the evaluation of HIV [27], [28], [29] and [30], foot and mouth disease virus [31] and H5N1 avian Influenza virus [32] antibody specificities, but we believe this is the first time that this approach has been used to examine HPV vaccine antibody specificity. Differences between pseudovirus neutralizing and VLP binding antibody profiles were stark. There are likely several confounding factors that contribute to this outcome including ABT-888 nmr technical differences between the assays and differences between the range of binding and neutralizing antibody specificities generated. Thus, while L1 VLP binding may be a useful surrogate for type-specific vaccine antibody responses [25] they may not be a similarly useful surrogate for neutralizing antibody reactivity against non-vaccine types. A

number of murine MAbs are capable of binding L1 VLP but lack the ability to neutralize the homologous L1L2 pseudovirus [17], [33], [34] and [35]. For example, MAb H16.J4 cross-reacts

with L1 VLP representing various HPV types by ELISA [17], cross-neutralizes HPV31, HPV33 and HPV58 in an L1-based reporter transduction assay [36], but poorly recognizes its epitope on HPV16 L1L2 pseudoviruses [34] and [35]. Conversely, the neutralizing type-specific MAb H16.V5 appears to recognize its epitope on L1 VLP and L1L2 pseudoviruses to a similar extent [35]. It is reasonable to assume, therefore, that the majority of non-neutralizing antibodies in vaccine sera that recognize VLP representing non-vaccine types, bind from to portions of the L1 protein not involved in (pseudo)virus entry or to domains that become altered when L2 is incorporated into the capsid. There was some agreement in the antigenic inter-type ranking of target HPV types. For both L1 VLP and L1L2 pseudovirus antigens, HPV31 was ranked as the nearest relative to HPV16, and both HPV33/HPV58 and HPV35/HPV52 appeared to share some antigenic similarity, at least based upon reactivity of antibodies generated against the archetypal Alpha-9 group type, HPV16. Some of these antigenic similarities could have been predicted from the distance matrix based upon the L1 amino acid sequence (HPV33 and HPV58), while some could not (HPV35 and HPV52). Hierarchical clustering of the pseudovirus neutralization data also suggested that Cervarix® vaccination elicits multiple cross-reactive antibody specificities.